---
url: https://www.servicesaustralia.gov.au/crohns-disease-toxicity-and-severity-descriptors
title: Crohn's disease toxicity and severity descriptors - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:44:00.260Z
source: servicesaustralia.gov.au
---
# Crohn's disease toxicity and severity descriptors

Toxicity and severity descriptors for treatments required to be trialled before accessing PBS-subsidised biological medicines to treat Crohn's disease.

## on this page

-   [Prednisolone](#a1)
-   [Azathioprine](#a2)
-   [Mercaptopurine](#a3)
-   [Methotrexate](#a4)

## Prednisolone

Adverse event

Brief description of minimum grade

National Institutes of Health common toxicity criteria grade

**Gastrointestinal**

Gastric irritation or ulcer

Requiring medical management

2 (or higher)

Nausea

Oral intake significantly reduced

2 (or higher)

Vomiting

2 or more episodes in 24 hours over pre-treatment

2 (or higher)

Weight gain

≥ 20% weight gain

3 (or higher)

**Cardiovascular**

Hypertension

Requiring therapy or more intensive therapy than previously

3 (or higher)

Fluid retention

Symptomatic, limiting function, unresponsive to therapy or requiring drug discontinuation

3 (or higher)

**Central nervous system**   
past psychiatric history is not a contraindication

Insomnia

Frequent insomnia interfering with activities of daily living

3 (or higher)

Mood alteration

Severe mood alteration interfering with activities of daily living

3 (or higher)

Personality or behaviour

Disruptive to patient or family, requiring mental health intervention

3 (or higher)

Restlessness

Severe

3 (or higher)

**Dermatological**

Acne or dermatological conditions

Severe

3 (or higher)

Purpura or bruising

Generalised or mucosal petechiae

3 (or higher)

Impaired healing

Requiring medical management

2 (or higher)

**Laboratory**

Hyperglycaemia

Glucose 13.9 mmol per L or higher

3 (or higher)

Hypertriglyceridaemia

\> 5-10 x upper limit of normal

3 (or higher)

Hypokalaemia

< 3.0 mmol per L

3 (or higher)

**Endocrine**

Cushingoid appearance

Present

3 (or higher)

Disordered menstruation

Very irregular over pre-treatment

2 (or higher)

**Ocular**

Cataracts

Symptomatic visual loss requiring treatment or interfering with function

3 (or higher)

Glaucoma

Increase in intraocular pressure with retinal changes

2 (or higher)

**Musculoskeletal**

Osteoporosis or fracture

Symptomatic, interfering with activities of daily living

 

Avascular necrosis

Symptomatic, interfering with function

2 (or higher)

Myopathy

Symptomatic, interfering with function

2 (or higher)

**Miscellaneous**

Immunosuppression

Severe, requiring treatment withdrawal

 

Impaired healing

Symptomatic, interfering with activities of daily living

 

Growth retardation

 

 

## Azathioprine

Adverse event

Brief description of minimum grade

National Institutes of Health common toxicity criteria grade

**Neoplasms**

New malignancy

Serious malignancy present

4

**Gastrointestinal**

Nausea

Oral intake significantly reduced

2 (or higher)

Vomiting

2 or more episodes in 24 hours over pre-treatment

2 (or higher)

Diarrhoea

Increase of more than 4 stools per day over pre-treatment, or incontinence

2 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but can eat or swallow

2 (or higher)

Abdominal pain

Severe pain, analgesia interfering with activities of daily living

3 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x upper limit of normal

2 (or higher)

Hepatic enzymes

\> 2.5 x upper limit of normal

2(or higher)

**Dermatological**

Rash

Rash with associated symptoms over less than 50% of body surface

2 (or higher)

Alopecia

Pronounced hair loss

3 (or higher)

**Pulmonary**

Pneumonitis

X-ray changes, requiring steroids and diuretics

2 (or higher)

**Miscellaneous**

Hypersensitivity

Rash, drug fever >38 °C, aches, etc.

2 (or higher)

Immunosuppression or atypical infection

Severe or systemic infection requiring intravenous antimicrobial treatment or hospitalisation

3 (or higher)

**Haematological**

Leukocytes

< 2 x 109 per L

3 (or higher)

Haemoglobin

< 80 g per L

3 (or higher)

Thrombocytes

< 50 x 109 per L

3 (or higher)

## Mercaptopurine

Adverse event

Brief description of minimum grade

National Institutes of Health common toxicity criteria grade

**Haematological**

Leukocytes

< 2 x 109 per L

3 (or higher)

Haemoglobin

< 80 g per L

3 (or higher)

Thrombocytes

< 50 x 109 per L

3 (or higher)

**Neoplasms**

 

 

New malignancy

Serious malignancy present

4

**Gastrointestinal**

Nausea

Oral intake significantly reduced

2 (or higher)

Vomiting

2 or more episodes in 24 hours over pre-treatment

2 (or higher)

Diarrhoea

Increase of more than 4 stools per day over pre-treatment, or incontinence

2 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but can eat or swallow

2 (or higher)

Abdominal pain

Severe pain, analgesia interfering with activities of daily living

3 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x upper limit of normal

2 (or higher)

Hepatic enzymes

\> 2.5 x upper limit of normal

2 (or higher)

**Dermatological**

Rash

Rash with associated symptoms over less than 50% of body surface

2 (or higher)

Alopecia

Pronounced hair loss

3 (or higher)

**Pulmonary**

Pneumonitis

X-ray changes, requiring steroids and diuretics

2 (or higher)

**Miscellaneous**

Hypersensitivity

Rash, drug fever >38 °C, aches, etc.

2 (or higher)

Immunosuppression or atypical infection

Severe or systemic infection requiring intravenous antimicrobial treatment or hospitalisation

3 (or higher)

## Methotrexate

Adverse event

Brief description of minimum grade

National Institutes of Health common toxicity criteria grade

**Alimentary tract**

Diarrhoea

Increase of more than 4 stools per day over pre-treatment, or incontinence

2 (or higher)

Nausea

Oral intake significantly decreased and symptoms that don't respond to at least 2 of the following:

-   reduction of the methotrexate dose
-   folinic acid or folic acid supplementation
-   switching from oral dosing to intramuscular dosing
-   splitting the methotrexate dose over 12 hours

A minimum of 3 doses of methotrexate should have been trialled

2 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but able to eat or swallow

2 (or higher)

Vomiting

2 or more episodes in 24 hours over pre-treatment

2 (or higher)

**Blood**

Haemoglobin

< 80 g per L

3 (or higher)

Clinical haemorrhage

Requiring transfusion

3 (or higher)

Leukocytes

< 2 x 109 per L

3 (or higher)

Phlebitis

Present

2 (or higher)

Thrombocytes

< 50 x109 per L

3 (or higher)

**Central nervous system**

Ataxia

Mild symptoms interfering with function but not interfering with activities of daily living

2 (or higher)

Hearing

Tinnitus or hearing loss not requiring treatment

2 (or higher)

Incoordination

Mild symptoms interfering with function but not interfering with activities of daily living

2 (or higher)

Mood alteration

Moderate mood alteration interfering with function but not interfering with activities of daily living

2 (or higher)

Vision

Symptomatic and interfering with function but not interfering with activities of daily living

3 (or higher)

**Dermatological**

Alopecia

Pronounced hair loss

2 (or higher)

Rash

Rash with associated symptoms over less than 50% of body surface

2 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x upper limit of normal

2 (or higher)

Elevated transaminases

-   Alanine aminotransferase and/or aspartate aminotransferase > 2.5 x upper limit of normal  
    or
-   Alanine aminotransferase and/or aspartate aminotransferase > 1.5 x upper limit of normal on 3 occasions over a 3-month period

2 (or higher)

Elevated serum alkaline phosphatase

2.5 x upper limit of normal

2 (or higher)

**Respiratory**

 

Pneumonitis/pulmonary infiltrates

Radiographic changes requiring steroids/diuretics

2 (or higher)

Pulmonary fibrosis

Requiring steroids/diuretics

2 (or higher)

Cough (severe)

Severe cough/coughing spasm that is poorly controlled or unresponsive to treatment. Evidence of reversal on treatment withdrawal

3 (or higher)

**Renal**

Renal impairment

Creatinine clearance <30 mL/min

3 (or higher)

**Other**

Allergic reaction

Urticaria, drug >38 °C or bronchospasm

2 (or higher)

Infection

Severe, systemic infection, requiring IV antimicrobial treatment or hospitalisation

3 (or higher)

Headaches (severe)

Severe pain (requiring compound analgesics) where pain/analgesics severely interfere with activities of daily living

3 (or higher)

Nodulosis (following introduction of methotrexate therapy)

Development of multiple new nodules causing significant local pressure symptoms and distress to the patient
